Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marisa Calabuig"'
Publikováno v:
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 15(6)
The antiangiogenic and immunomodulatory properties of thalidomide have led to its use and evaluation in refractory or relapsed multiple myeloma (MM). 1,2 However, thalidomide use is associated with several side effects, although deep vein thrombosis
Autor:
Josefina Serrano, Diana Buenasmañanas, P Herrera, Mari Luz Amigo, Marisa Calabuig, Eusebio Martin, Maria-Belén Vidriales, Adolfo de la Fuente, M Santero, Silvia Negri, Jose Gonzalez-Campos, Carmen Albo, Sonia Gonzalez, Jose J. Rifon, M Cruz Viguria, V Garcia-Gutierrez, Carmen Martin, Joaquin Sanchez-Garcia
Publikováno v:
Blood. 122:3410-3410
HCT is the only potentially curative approach that may provide long-term disease control for patients con relapsed and/or refractory acute leukemia (Re/Ref AL). However, active disease burden at HCT is associated with high relapse rates and dismal ou
Autor:
Ana Garrido, Rafael F. Duarte, Marisa Calabuig, Olga Salamero, Carmen Pedro, Jordi Esteve, Montserrat Arnan, Josep F. Nomdedeu, Joan Bargay, Andreu Llorente, Jorge Sierra, David Gallardo, Susana Vives, M. Paz Queipo De Llano, Josep-Maria Ribera, Salut Brunet, Marta Pratcorona, Montserrat Hoyos, Juan Besalduch, Ramon Guardia, Mar Tormo
Publikováno v:
Blood. 122:2107-2107
Introduction The improvements in genetic characterization of AML allowed the ELN to propose a prognostic classification into 4 categories: Favorable, Intermediate I, Intermediate II and Adverse. Several groups have tested the outcome of AML patients
Autor:
Marina Gordillo, Teresa Olave, Guillermo Deben, Juan Bergua, Jose Francisco Tomas, Angeles Fernandez, Sonia Gonzalez, Concha Bethencourt, Daniel Garcia Belmonte, Ana Belen Santos, Mar Caballero, Adolfo de la Fuente, Dolores Vilariño, Silvia Negri, Rosa Fernandez Martinez, Alejandro Román, Federico Moscardó, Jose Luis Lopez Lorenzo, Mar Tormo, Jl Sastre Moral, Silvia Solorzano, Marisa Calabuig, Pilar Martínez-Sánchez, Pascual Fernández-Abellán
Publikováno v:
Blood. 118:4279-4279
Abstract 4279 Introduction: Clofarabine (CLF) is a purine nucleoside analog approved by FDA and EMA in refractory pediatric ALL patients. Phase I and II studies have reported Clofarabine activity in AML. Aims: To evaluate the experience in Spain with